



UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS  
UNITED STATES PATENT AND TRADEMARK OFFICE  
WASHINGTON, D.C. 20231  
[www.uspto.gov](http://www.uspto.gov)

APPLICATION NUMBER	FILING/RECEIPT DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NUMBER
10/032,241	12/21/2001	L. Kathryn Durham	PC11028AJAK

## CONFIRMATION NO. 6632

## FORMALITIES LETTER



\*OC000000007382643\*

Gregg C. Benson  
Pfizer Inc.  
Patent Department, MS 4159  
Eastern Point Road  
Groton, CT 06340

Date Mailed: 01/29/2002

## NOTICE TO FILE CORRECTED APPLICATION PAPERS

*Filing Date Granted*

This application has been accorded an Application Number and Filing Date. The application, however, is informal since it does not comply with the regulations for the reason(s) indicated below. Applicant is given **TWO MONTHS** from the date of this Notice within which to correct the informalities indicated below. Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 CFR 1.136(a).

The required item(s) identified below must be timely submitted to avoid abandonment:

- Substitute drawings in compliance with 37 CFR 1.84 because:
  - drawing sheets do not have the appropriate margin(s) (see 37 CFR 1.84(g)). Each sheet must include a top margin of at least 2.5 cm. (1 inch), a left side margin of at least 2.5 cm. (1 inch), a right side margin of at least 1.5 cm. (5/8 inch), and a bottom margin of at least 1.0 cm. (3/8 inch);
- A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing." Applicant must provide a substitute computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d).

For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (703) 308-4216
- To Purchase PatentIn Software, call (703) 306-2600
- For PatentIn Software Program Help, call (703) 306-4119 or e-mail at [patin21help@uspto.gov](mailto:patin21help@uspto.gov) or [patin3help@uspto.gov](mailto:patin3help@uspto.gov)

*A copy of this notice MUST be returned with the reply.*



Customer Service Center

Initial Patent Examination Division (703) 308-1202

PART 2 - COPY TO BE RETURNED WITH RESPONSE



T.D. BOX Sequence  
Patent  
Attorney Docket No. PC11028AGPR  
0300

I hereby certify that this correspondence is being deposited with the United States Postal Service as first-class mail in an envelope addressed to U.S. Patent and Trademark Office, Box Sequence, P.O. Box 2327, Arlington, VA 22202 on this 29th day of May, 2002.

By \_\_\_\_\_

*Janice M. Denison*  
(Signature of person mailing)  
Janice M. Denison  
(Typed or printed name of person)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: **L. Kathryn Durham, et al.** :

APPLICATION NO.: **10/032,241** : Examiner: **To be assigned**

FILING DATE: **12/21/01** : Group Art Unit: **1614**

TITLE: **Methods, Compositions, and Kits Relating to  
Cardiovascular Disease**

U.S. Patent and Trademark Office  
Box Sequence, P.O. Box 2327  
Arlington, VA 22202

RESPONSE TO NOTICE TO FILE CORRECTED APPLICATION PAPERS

In response to the formalities letter (copy included) mailed January 29, 2002, having an extendable response due date of March 29, 2002, and extended by two months, provided on this date herewith is a substitute CRF (one disk) as required by 37 C.F.R. §1.822 and/or 1.823, together with a statement that the content of the sequence listing information recorded in the substitute CRF is identical to the written sequence listing. Further included, for convenience, is a copy of the written sequence listing which is identical to that which was previously submitted; hence, no new matter is being submitted.

Also, please find a copy of the substitute drawings in compliance with 37 CFR §1.84

Date: 5/29/02

Respectfully submitted,

*Gregory P. Raymer*  
Gregory P. Raymer  
Attorney for Applicant(s)  
Reg. No. 36,647

Pfizer Inc.  
Patent Department, MS 8260-1611  
Eastern Point Road  
Groton, Connecticut 06340  
(860) 715-5746